SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024), scheduled for March 20-23, 2024 in Prague, Czech Republic.

上海和剑桥，马萨诸塞州。-（商业新闻短讯）--Zai实验室有限公司（纳斯达克：ZLAB；香港交易所：9688）今天宣布，它将展示临床前研究的结果，突出ZL-1310的治疗潜力，ZL-1310是该公司的全球下一代抗体-药物偶联物（ADC）计划。ZL-1310的临床前概况将成为2024年3月20日至23日在捷克共和国布拉格举行的2024年欧洲肺癌大会（ELCC 2024）海报展示的重点。

ZL-1310 is a novel and promising ADC within the Zai Lab global oncology R&D pipeline, targeting the Delta-like ligand 3 (DLL3), a validated therapeutic target in the treatment of small cell lung cancer (SCLC). DLL3, which is expressed on the cell surface of most SCLC, plays a pivotal role in promoting SCLC cell proliferation, migration and invasion.

ZL-1310是Zai实验室全球肿瘤学研发管道中一种新型且有前景的ADC，靶向δ样配体3（DLL3），这是治疗小细胞肺癌（SCLC）的有效治疗靶点。DLL3在大多数SCLC的细胞表面表达，在促进SCLC细胞增殖，迁移和侵袭中起着关键作用。

“ZL-1310 has high affinity for the target, DLL3, and releases its payload both intracellularly and in the tumor microenvironment, also allowing for bystander effect of its camptothecin-derived payload,” said Rafael G. Amado, M.D., president, head of Global Oncology Research and Development, Zai Lab.

“ZL-1310对靶标DLL3具有很高的亲和力，并在细胞内和肿瘤微环境中释放其有效载荷，也允许其喜树碱衍生有效载荷的旁观者效应，”Zai实验室全球肿瘤学研究与发展负责人Rafael G.Amado医学博士说。

“The encouraging preclinical data we will present at ELCC 2024 formed the basis for the ZL-1310 Phase 1 clinical trial that we initiated in January of this year.”

“我们将在ELCC 2024上提供令人鼓舞的临床前数据，为我们今年1月启动的ZL-1310 1期临床试验奠定了基础。”

Data from the preclinical IND-enabling studies which will be shared at ELCC 2024 indicate that ZL-1310 exhibits a strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest and the induction of apoptosis in tumor cells. In-vivo, ZL-1310 effectively suppressed the growth of established human tumors in a dose-dependent manner in both cancer cell-derived (CDX) and SCLC patient sample-derived (PDX) xenograft models.

将在ELCC 2024上共享的临床前IND支持研究的数据表明，ZL-1310与细胞表面的DLL3表现出强烈而特异的结合，导致肿瘤细胞的内化，细胞周期停滞和凋亡诱导。在体内，ZL-1310在癌细胞衍生（CDX）和SCLC患者样品衍生（PDX）异种移植模型中均以剂量依赖性方式有效抑制已建立的人类肿瘤的生长。

ZL-1310 was discovered with MediLink Therapeutics’ proprietary TMALIN® platform, a next-generation ADC platform designed to leverage the tumor microenvironment to overcome the challenges with current ADC drugs. Zai Lab entered a partnership and exclusive worldwide license agreement with MediLink in April 2023.

ZL-1310是通过MediLink Therapeutics专有的TMALIN®平台发现的，该平台是一种新一代ADC平台，旨在利用肿瘤微环境来克服当前ADC药物的挑战。2023年4月，Zai实验室与MediLink签订了合作伙伴关系和全球独家许可协议。

Subsequently, in January 2024, Zai Lab initiated a global Phase 1 study of ZL-1310 in patients with relapsed and refractory SCLC who have progressed after platinum-based treatment.

随后，2024年1月，Zai实验室启动了一项针对复发和难治性小细胞肺癌患者的ZL-1310全球1期研究，这些患者在铂类治疗后取得了进展。

Details regarding the poster presentation at ELCC 2024 are as follows:

ELCC 2024海报展示详情如下：

Title: Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors

标题：用于治疗实体瘤的新型DLL3靶向抗体-药物偶联物（ADC）的开发和表征

Presenter: Linda N Liu, Senior Vice President, Biologics Discovery, Zai Lab

主持人：Linda N Liu，Zai实验室生物制剂发现高级副总裁

Date/Time: Friday, March 22, 2024, 12:00 PM - 12:45 PM CET

日期/时间：2024年3月22日，星期五，下午12:00

Location: Prague Congress Centre, Congress Hall Foyer

地点：布拉格会议中心，国会大厅大厅

About Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors

关于小细胞肺癌（SCLC）和神经内分泌肿瘤

SCLC and neuroendocrine tumors are diseases with significant unmet medical needs globally. There are over 300,000 SCLC annual incidences globally.1 More than 88% of SCLC patients overexpress DLL3 and could benefit from targeted therapeutic agents.2 In addition, DLL3 is a promising target highly expressed in several tumors with neuroendocrine features.

小细胞肺癌和神经内分泌肿瘤是全球医疗需求严重未得到满足的疾病。全球每年有超过300000例SCLC发病率。超过88%的SCLC患者过度表达DLL3，并可能受益于靶向治疗药物。此外，DLL3是一种有前景的靶点，在几种具有神经内分泌特征的肿瘤中高度表达。

There are approximately 171,000 people living with neuroendocrine tumors in the United States, and the numbers are continuing to increase, but the treatment options remain limited.3.

在美国，大约有171000人患有神经内分泌肿瘤，并且数量正在继续增加，但治疗选择仍然有限。

About Zai Lab

关于Zai实验室

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience.

Zai Lab（纳斯达克股票代码：ZLAB；香港交易所代码：9688）是一家位于中国和美国的创新型、研究型、商业化生物制药公司。我们专注于发现、开发和商业化创新产品，以解决肿瘤学、自身免疫性疾病、传染病和神经科学领域严重未满足需求的医疗条件。

Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

我们的目标是利用我们的能力和资源，对中国和全球的人类健康产生积极影响。